pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Obesity · news · pharmadog
← back to Obesity
News mentioning Obesity
549
stories
5d
#EASD26: Zealand and Roche's amylin works best at middle dose, trails Lilly's
endpoints
5d
#EASD26: Lilly's triple-G allows 60% of patients to drop below obesity threshold
endpoints
5d
STAT+: Lawmakers urge Trump to rethink new rule that could restrict imported meds from Canada and overseas
stat
5d
STAT+: Beam Therapeutics sues Chinese biotech, VC-backed startup, alleging theft of intellectual property
stat
5d
Novo to pay Hengrui up to $2.6B for a once-weekly obesity pill
biopharma dive
6d
Roche cuts muscle-sparing obesity drug after mid-stage disappointment
biospace
6d
STAT+: AstraZeneca invests $2 billion in Summit Therapeutics
stat
6d
STAT+: Pharmalittle: We’re reading about Novo licensing a Chinese obesity pill, Merck pulling an antibiotic, and more
stat
6d
Novo adds long-term obesity differentiation in up to $2.6B Hengrui deal
biospace
6d
STAT+: UniQure’s gene therapy continues to slow Huntington’s progression after four years
stat
6d
Novo to spend $300M upfront to license Hengrui's weekly oral weight loss drug
endpoints
6d
Opinion: Child health is the national security crisis we keep ignoring
stat
6d
STAT+: Drug pricing, Medicaid, and research funding: The key policy issues at stake in the midterms
stat
6d
Novo agrees $2.6B deal for preclinical GLP-1/GIP drug from in-demand Hengrui
fiercebiotech
6d
Recon: FDA approves Egetis’ Emcitate for rare genetic disease; Novo buys rights to Chinese weight-loss pill in $2.6B deal
raps
7d
Roche cans muscle-preserving obesity drug, hands it back to Chugai
endpoints
7d
STAT+: AbbVie wins FDA nod for Parkinson’s pill
stat
7d
STAT+: Pharmalittle: We’re reading about GLP-1s becoming lifestyle drugs, a setback for Merck and Daiichi, and more
stat
7d
Trump uses ‘contested’ power to cut more funding to HHS
stat
7d
Roche drops muscle-sparing obesity antibody after flunked interim analysis
fiercebiotech
7d
STAT+: Once described as obesity medicines for ‘patients,’ GLP-1s are increasingly lifestyle drugs for ‘customers’
stat
7d
6 immunology targets to sustain a mammoth I&I market
biospace
9d
This week in charts: Novo’s rise and fall and AI biotechs’ big haul
biopharma dive
10d
STAT+: Pharmalittle: We’re reading about a reticent FDA commish nominee, a Novo deal, and more
stat
10d
Novo pursues long-acting obesity drugs; Acadia slumps on Alzheimer’s data
biopharma dive
10d
Novo inks $1.3B Nanexa deal to unlock long-acting obesity injectables
fiercebiotech
10d
ADARx scores upsized $446M IPO, while fellow RNA biotech City maps out Nasdaq plans
fiercebiotech
10d
RNAi drug specialist ADARx raises $446M IPO
biopharma dive
10d
Pioneer of China NewCo model sued in US over trade secret misuse, double-dealing
fiercebiotech
10d
The FDA’s Overton era, and dispatches from Shanghai
stat
← prev
page 2 of 19
next →
